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ABSTRACT  
Pseudomonas aeruginosa is a challenging bacterium to treat due to its intrinsic antibiotic 
resistance to the most frequently used antibiotics in patients with community-acquired 
pneumonia (CAP). Data about the global burden and risk factors associated with P. aeruginosa-
CAP are limited. We assessed the multinational burden and specific risk factors associated with 
P. aeruginosa-CAP. 
 
We enrolled 3,193 patients in 54 countries with confirmed diagnosis of CAP that underwent 
microbiological testing at admission. Prevalence was calculated according to the identification of 
P. aeruginosa. Logistic regression analysis was used to identify risk factors for antibiotic-
susceptible and antibiotic-resistant P. aeruginosa-CAP. 
 
The prevalence of P. aeruginosa and antibiotic-resistant P. aeruginosa-CAP was 4.2% and 
2.0%, respectively. The rate of P. aeruginosa CAP in patients with prior infection/colonization 
due to P. aeruginosa and at least one of the three independently associated chronic lung diseases 
[i.e., tracheostomy, bronchiectasis and/or very severe COPD]) was 67%. In contrast, the rate of 
P. aeruginosa CAP was 2% in patients without prior P. aeruginosa infection/colonization and 
none of the selected chronic lung diseases.  
 
The multinational prevalence of P. aeruginosa-CAP is low. The risk factors identified in this 
study may guide healthcare professionals in deciding empirical antibiotic coverage for CAP 
patients. 
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INTRODUCTION 
Community acquired pneumonia (CAP) is a leading infectious cause of morbidity and 
mortality worldwide[1, 2]. Five to six billion people are diagnosed with CAP and more than 3.5 
million people die annually secondary to CAP[1, 3]. Several viruses and bacteria cause CAP[4], 
but Streptococcus pneumoniae remains the most frequently identified bacterial pathogen in 
adults[5]. During the last few decades, the aetiology of CAP has been changing; antibiotic-
resistant bacteria that were thought to be important only in hospital settings are now becoming 
more prevalent in community settings[6-8]. The evolution of this new pathogen ecology is 
threatening our capacity to treat patients with CAP[9-11].  
Pseudomonas aeruginosa, a Gram-negative bacterium, intrinsically resistant to several 
groups of antibiotics, such as β-lactams[12], has been frequently reported in CAP patients with 
specific health care associated risk factors, such as residence in a nursing home and 
hospitalization during the past 90 days (i.e., health care associated pneumonia, HCAP) [13-15]. 
Moreover, severe illnesses and poor clinical outcomes have been linked to P. aeruginosa 
infection in patients with CAP[15-17]. During recent years, P. aeruginosa circulating strains 
tend to have higher resistance patterns to anti-pseudomonal antibiotics, leading to infections that 
are challenging to treat[6].  
The prevalence of CAP due to P. aeruginosa varies significantly between different 
patient groups and specific risk factors for P. aeruginosa-CAP are controversial[18, 19]. 
Currently available data about the prevalence of P. aeruginosa-CAP and its resistance patterns 
4
 are limited to single centre studies[15, 20] and studies with several methodological 
limitations[15, 21-23]. In a meta-analysis, Chalmers et al. reported data from 22 studies a 
prevalence ranging from 0 to 23% in different CAP populations and a pool prevalence of 8.6% 
for P. aeruginosa in patients with multidrug resistant risk factors and 4% in patients without risk 
factors[24]. All were single centre/region and majority were rated as poor methodological 
status[24]. As a result, the true prevalence of P. aeruginosa-CAP globally is unknown. 
Currently, the risk factors associated with P. aeruginosa infection recognised by Infectious 
Diseases Society of America/ American Thoracic Society (IDSA/ATS) guidelines for HCAP 
differ from those published in the CAP guidelines [13, 25]. Further, the global prevalence of 
multi-drug resistant (MDR) P. aeruginosa in CAP patients is unknown. Therefore, to close the 
gap regarding the global prevalence and the risk factors associated with P. aeruginosa, we 
designed a multinational, multicentre, worldwide study to determine the point prevalence of P. 
aeruginosa, its antibiotic resistance patterns, and the associated risk factors in hospitalised 
patients with CAP. 
 
MATERIALS AND METHODS 
Study Design 
This is a multicentre, point-prevalence study of hospitalised patients with CAP in 222 
hospitals in 54 countries. The coordinating institution for this project was the University of 
Texas Health San Antonio (UT Health) in San Antonio, Texas, USA. The UT Health 
Institutional Review Board approved the project to collect data and serve as a coordinating 
institution for the study (IRB# HSC20150184E). Study sites had to comply with local and 
national research regulations to participate in the study. Electronic invitations to participate were 
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 sent to members of various medical professional societies representing physicians specializing in 
infectious diseases, pulmonary, critical care, and internal medicine. Additionally, first authors of 
previously published studies of MDR pathogens in CAP were sent individual invitations. This 
project received no funding. Subjects were enrolled on four randomly selected days in March, 
April, May, and June of 2015. Each site investigator selected the study days to participate in 
compliance with the IRB stipulations, and avoid potential patient de-identification[26]. Due to 
the observational nature of the study, patient consent was not required.  
 
Study Subjects 
Inclusion criteria  
Patients ≥18 years of age hospitalised with CAP were eligible for the study. CAP had to 
be diagnosed per the current IDSA/ATS guidelines[13]: presence of new pulmonary infiltrates 
on thoracic imaging (chest radiograph, computed chest tomography, or lung ultrasound) during 
the initial 48 hours of hospitalization and ≥1 of the following conditions: 1) novel or increased 
cough with or without sputum production and/or purulent respiratory secretions; 2) fever (oral or 
rectal temperature ≥37.8 ° C) or hypothermia (oral or rectal temperature <36 ° C); 3) signs of 
systemic inflammation (abnormal white blood cell count [leucocytosis >10,000/cm3, bandemia 
>10%, leukopenia <4,000/cm3], procalcitonin levels above the local upper limit of normal, or 
increased C-reactive protein)[26].  
 
Exclusion criteria  
Patients were excluded from participating in the study if they had hospital-acquired 
pneumonia (HAP) or ventilator associated pneumonia (VAP)[25]. Patients without 
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 microbiological testing from either blood, lower respiratory tract cultures, or sputum collected 
within 24 hours of hospital admission were also excluded. 
 
 
Data collection  
Data was collected and managed using REDCap™ (Research Electronic Data Capture), 
an electronic data capture tool hosted on the UT Heath San Antonio’s server. REDCap™ is a 
protected web-based application designed to collect research data[27]. Confirmation of 
microbiological results and all electronic data entry had to be completed within 7 days of study 
enrolment.  
 
Microbiological analysis 
Diagnostic testing, such as blood cultures and respiratory collection; and clinical care 
decisions were decided by attending physicians, not per study protocol[26]. Local 
microbiological testing protocols were used to process blood and sputum samples collected 
within the first 24 hours of hospitalization. If available, data on pleural fluid, tracheobronchial 
aspirate, and bronchoalveolar lavage fluid were collected. Local testing executed by each 
hospital included respiratory and blood cultures, urinary antigen and drug susceptibility testing. 
Local quality control protocols for Minimum Inhibitory Concentration (MIC) breakpoints and 
Clinical and Laboratory Standards Institute (CLSI) or the European Committee on Antimicrobial 
Susceptibility Testing (EUCAST) standards were followed according with local regulations and 
protocols[28, 29]. 
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 Study definitions  
Patients that required invasive respiratory and/or vasopressor support (IRVS) during 
initial 24 hours of hospitalization were categorised as IRVS+[30]. P. aeruginosa-CAP was 
defined as any patient with a confirmed diagnosis of CAP in whom P. aeruginosa was isolated in 
any respiratory fluid, including pleural effusion, sputum and/or bronchoalveolar lavage, and/or in 
the blood. Drug-resistant P. aeruginosa was defined when the isolated pathogen was resistant to 
≥1 antibiotic and MDR P. aeruginosa was defined by resistance to ≥3 of the evaluated 
antibiotics. Antibiotic resistance to the following anti-pseudomonal antibiotics were evaluated: 
piperacillin/tazobactam, cefepime, ceftazidime, amikacin, gentamicin, tobramycin, levofloxacin, 
ciprofloxacin, imipenem, meropenem, doripenem, colistin and polymyxin B. 
Prior P. aeruginosa infection/colonization was defined as confirmed 
infection/colonization within the last year before the hospitalization, documented by the patient 
or available patient records. Chronic obstructive pulmonary disease (COPD) was defined 
according to FEV1/FVC ratio <0.7 and a compatible clinical history (including smoking history 
if relevant). Very severe COPD was defined as patients with COPD with evidence of very severe 
obstruction, determined by FEV1 <30% prior to hospital admission (see online supplement for 
the complete study dictionary). Site investigators were given these definitions in the study 
protocol manual and study dictionary prior to starting data collection[26]. 
 
Statistical analysis  
The prevalence of P. aeruginosa as microbiological aetiology of CAP (i.e., P. 
aeruginosa-CAP) was calculated based on the counts of P. aeruginosa isolates divided by the 
study cohort (i.e., CAP patients with microbiological test done), and is expressed as percentages. 
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 Chi-squared tests were used to compare categorical variables, which were expressed as counts 
and percentages. Continuous variables are presented as medians with interquartile ranges (IQR) 
and nonparametric Mann-Whitney U test was used to compare them. To assess the relationship 
between CAP due to P. aeruginosa and 67 demographic, clinical, epidemiological, and treatment 
variables, stepwise logistic regression model was executed. P-value<0.05 was defined as 
statistically significant. Tableau desktop, professional edition for Mac, was used to generate 
prevalence maps. All statistical analyses were performed with IBM SPSS, Statistics for Mac, 
version 22.0, Armonk, NY: IBM Corp. 
 
RESULTS 
A total of 3,193 patients were recruited during four study days from 222 hospitals in 54 
countries (1,877 [58.8%] males, median [IQR] age: 68 [54-80] years). The demographics, risk 
factors, comorbidities, severity of illness, and chronic treatments are reported in Table 1. Among 
the 6 continents, most patients were recruited from Europe (1,941 [60.8%]), followed by North 
America (484 [15.2%]), Asia (405 [12.7%]), South America (203 [6.4%]), Africa (128 [4.0%]) 
and Oceania (32 [1.0%]). Microbiological cultures were obtained from blood (2,211 [69.2%]), 
sputum (1,630 [51.0%]), and bronchoalveolar lavage (311 [9.7%]). At least one pathogen was 
identified in 1,173 patients (36.7%), Figure e1. Tables 2 and e1 display the prevalence of P. 
aeruginosa-CAP and antibiotic-resistant P. aeruginosa-CAP per continents and countries. 
 
Prevalence of Pseudomonas aeruginosa-CAP  
P. aeruginosa-CAP was identified in 133 (4.2%) patients, representing 11.3 % 
(133/1,173) of all patients that had a positive culture for bacterial pathogens. The continental 
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 prevalence of P. aeruginosa-CAP was, 3.8% in Europe, 4.3% in North America, 5.2% in Asia, 
4.9% in South America, 5.5% in Africa and 3.1% in Oceania, respectively (Figure 1). The 
prevalence of P. aeruginosa-CAP in each country, and a comparison between continents and 
countries is shown in Table 2 and e1. No statistically significant difference was found in the 
prevalence of P. aeruginosa-CAP among different continents. Croatia was the only country with 
statistically significant higher prevalence of P. aeruginosa-CAP (Table e1). 
 
Prevalence of antibiotic-resistant P. aeruginosa-CAP  
Antibiotic-resistant P. aeruginosa-CAP was identified in 64 (2.0%) patients, representing 
5.4% (64/1,173) of all patients that had a positive culture. The continental prevalence of 
antibiotic-resistant P. aeruginosa-CAP was 1.6% in Europe, 2.5% in North America, 2.2% in 
Asia, 3.0% in South America, and 3.9% in Africa, respectively (Figure 1). There were no 
patients with antibiotic-resistant P. aeruginosa-CAP identified in Oceania. No statistically 
significant difference was found in the prevalence of antibiotic-resistant P. aeruginosa-CAP 
among different continents (Table 2). 
 
Prevalence of multi-drug resistant P. aeruginosa-CAP 
MDR P. aeruginosa was identified in 33 (1.0%) patients, representing 2.8% (33/1,173) of 
all patients that had a positive culture. The continental prevalence of MDR P. aeruginosa-CAP 
was 0.9% in Europe, 1.2% in North America, 0.5% in Asia, 2% in South America, and 2.3% in 
Africa, respectively. There were no patients with MDR P. aeruginosa identified in Oceania. No 
statistically significant difference was found in the prevalence of MDR P. aeruginosa-CAP 
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 among different continents. No patients were infected with pan-drug resistant P. aeruginosa (i.e., 
resistant to > 3 groups of antibiotics and colistin) [31]. 
 
 
Risk factors 
Patient demographics and risk factors were compared among P. aeruginosa-CAP and 
non-P. aeruginosa CAP (Table 1). The risk factors independently associated with P. aeruginosa-
CAP in the multivariate analysis were prior pseudomonas infection/colonization (OR: 16.10 95% 
CI: 9.48, 27.35), prior tracheostomy (OR: 6.50, 95% CI: 2.61, 16.19), bronchiectasis (OR: 2.88, 
95% CI: 1.65, 5.05), IRVS (OR: 2.33 95% CI: 1.44, 3.78) and very severe COPD (OR: 2.76 95% 
CI: 1.25, 6.06) (Table 3, Figure e2). Moreover, the risk factors associated with antibiotic-
resistant P. aeruginosa-CAP were prior pseudomonas infection/colonization (OR: 17.29, 95% 
CI: 9.95, 33.42), tracheostomy (OR: 5.55, 95% CI: 1.73, 17.80) and IRVS (OR: 3.12, 95% CI: 
1.63, 5.97). The risk factors found to be only statistically significant in the bivariate analysis 
were: COPD, coronary artery disease, inhaled corticosteroid use, indwelling catheter, and lower 
respiratory tract infection/ER visits/Hospitalisations/antibiotic treatments during the last 12 
months (Table e3). Table 3 shows all the risk factors that had a statistically significant 
association with the different antibiotic resistance patterns (multivariate analyses are presented in 
Tables e2).  
Figure 2 emphasizes the importance of the prevalence of P. aeruginosa-CAP, either one 
of the two main cluster of risk factors were tested among all the patients hospitalised with CAP 
or after stratifications based on the requirement of IRVS. Among all the patients with CAP, only 
11% had risk factors (previously infected/colonization by pseudomonas and had chronic lung 
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 diseases [i.e., tracheostomy, bronchiectasis and/or very severe COPD]). The lack of these two 
sets of risk factors (i.e., previously infected/colonization by pseudomonas and tracheostomy, 
bronchiectasis and/or very severe COPD based on FEV1) confirms that only 2-6% of patients 
might still be affected, independent of the need of IRVS. The sensitivity, specificity, 
positive/negative predictive values and positive/negative likelihood ratios of these risk factors 
are presented in table e3.  
 
DISCUSSION 
This multinational point-prevalence study found a low prevalence of P. aeruginosa 
among hospitalised patients with CAP. Only 4.2%, 2.0% and 1.0% of hospitalised patients had 
CAP due to P. aeruginosa, antibiotic-resistant P. aeruginosa, or multidrug-resistant (MDR) P. 
aeruginosa, respectively. No patients were identified with pan-drug resistant P. aeruginosa. 
There was no statistically significant difference in prevalence rates between different continents. 
Croatia was the only country with statistically significant higher P. aeruginosa-CAP prevalence. 
Prior pseudomonas infection/colonization, tracheostomy, bronchiectasis, IRVS, and very severe 
COPD were independently associated with P. aeruginosa-CAP. Moreover, patients admitted 
with CAP with a past medical history of pseudomonas infection/colonization or chronic lung 
diseases (i.e., tracheostomy, bronchiectasis and/or very severe COPD) had a higher risk of being 
infected with antibiotic-resistant P. aeruginosa. 
Deciding empirical treatment for CAP patients has become challenging due to the 
emerging prevalence of drug-resistant bacteria, such as P. aeruginosa[6]. In a large retrospective 
study of culture positive patients in the United States, Kollef et al. reported a 19% prevalence of 
P. aeruginosa in hospitalised patients with CAP[15]. In a prospective cohort study in Europe, 
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 Chalmers et al. reported a 0.7% prevalence of P. aeruginosa among all patients enrolled with 
CAP and 2.2% among those with positive cultures[32]. Recently, Jain et al. found P. aeruginosa 
in 0.4% of patients with CAP in a prospective cohort study in the United States and 1% among 
the patients with culture positive pneumonia[5]. We found the multinational point prevalence of 
P. aeruginosa as the causative pathogen of CAP was 4.2%, which corresponds to 11.3% of 
patients with positive culture pneumonia. Variations in the prevalence rates reported by different 
studies may be explained by differences in study design, especially the denominator used to 
calculate the prevalence rates[26]. However, these newly reported prevalence rates of P. 
aeruginosa–CAP are lower than prior reports[13-15], suggesting that only a small subgroup of 
patients may require empiric anti-pseudomonal antibiotic coverage. 
The IDSA/ATS CAP guidelines recommend an antipseudomonal β-lactam antibiotic plus 
a fluoroquinolone or aminoglycoside in patients with risk factors for P. aeruginosa-CAP [13]. 
Dual antibiotic coverage has been recommended for HCAP, HAP, or VAP, where multidrug 
resistant pseudomonas is thought to be an important problem[25]. Our results challenge this 
approach, by showing that the worldwide prevalence of MDR P. aeruginosa in patients with 
CAP is very low (1% or 3% among culture positive pneumonia patients). Our results are 
consistent with the evidence from Spain by Cilloniz et al. who reported a prevalence of 
multidrug-resistant P. aeruginosa of 1.1% in a prospective cohort study of culture positive CAP 
patients[33]. Therefore, the recommended use of double antipseudomonal empirical coverage 
overestimates the actual rates of multidrug-resistant P. aeruginosa compared to what it is found 
in infections acquired in hospital settings, where the resistance rates seems to be higher than in 
patients coming from the community. However, it is suggested that patients critically ill with 
septic shock due to pneumonia should receive empiric double antipseudomonal coverage[25]. 
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 Several researchers have hypothesised that studies assessing the prevalence of pathogens 
responsible for CAP are difficult to generalize because these studies are conducted in different 
environments (i.e., single hospital, regional, country or continent) with specific differences in 
healthcare delivery, including antibiotic availability and policies for antimicrobial use[19, 21, 23, 
34]. In our study, we found that the prevalence of P. aeruginosa-CAP was not significantly 
different between participating centres representing different continents. In contrast, Croatia was 
the only country that had statistically significant higher P. aeruginosa-CAP prevalence. This 
study is novel by enrolling patients in a large number of centres representing more than 50 
countries from all over the world to identify the prevalence of P. aeruginosa in CAP patients.   
In general, many hospitalised patients receive initial empiric anti-pseudomonal coverage 
while waiting 48-72 hours for specific pathogen identification and antibiotic susceptibilities[1, 
3].This practice has increased the use of broad-spectrum antibiotic agents and promoted 
antibiotic overuse with the risk of inducing antimicrobial resistance[11, 26]. Additionally, the 
delay between initial diagnosis and availability of antibiotic susceptibilities could negatively 
affect outcomes in patients with CAP due to inappropriate antibiotic coverage[13]. Therefore, 
initiation of empiric anti-pseudomonal coverage should be based on the likelihood that a 
pathogen circulates in the affected community and the presence of specific risk factors for P. 
aeruginosa-CAP[6, 13, 25]. In this regard, the risk factors listed in the IDSA/ATS pneumonia 
guidelines for P. aeruginosa-CAP are ICU admission, structural lung diseases, such as 
bronchiectasis, or COPD with multiple exacerbations[13]. Several risk factors have been 
reported for P. aeruginosa-CAP during the last few decades[6], but these previously reported 
risk factors (e.g., heart failure, tube feeding[35], etc.) were statistically significant in the bivariate 
analysis of our study, but not in the multivariable analysis. In contrast, we found that prior 
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 pseudomonas infection/colonization, prior tracheostomy, bronchiectasis, IRVS, and very severe 
COPD (FEV1 ≤30%) were independently associated with P. aeruginosa-CAP. These findings 
support the recommendation to consider these risk factors for empiric anti-pseudomonal 
antibiotics in patients with severe pulmonary diseases; but not in all patients with structural lung 
diseases. More importantly, patients with previous P. aeruginosa infection/colonization are at 
highest risk for P. aeruginosa-CAP and could benefit from empiric anti-pseudomonal antibiotic 
coverage, regardless of disease severity. Using these specific risk factors differs from the 
approach recommended by the IDSA/ATS guidelines and may help prevent overuse of anti-
pseudomonal antibiotics in patients with CAP. More importantly antimicrobial stewardship 
programs that attempt to minimize the use of anti-pseudomonal coverage among patients without 
the specific pseudomonas risk factors may help prevent adverse events and overuse of 
unnecessary antimicrobial therapies. 
This point prevalence study has some limitations. First, we were not able to determine 
clinical outcomes due to the study design. However, to determine prevalence rates and identify 
risk factors, point prevalence studies are ideal because they generate large sample sizes and 
gather generalizable data. Second, microbiological samples were not collected to do centralised 
antibiotic susceptibility testing due to the experimental design and feasibility. Nevertheless, 
laboratories at study sites were encouraged to follow the CLSI or EUCAST guidelines to 
determine antibiotic resistance[28, 29]. Third, microbiological diagnosis of patients with CAP 
could be confounded by other pathogens colonizing the respiratory tract; however, in our study 
we only reported pathogens with representative growth according to current clinical guidelines 
for CAP. Fourth, infections other than pneumonia are possible, but less likely to present in 
patients with clinical signs and symptoms and radiological confirmation of CAP. Fifth, quality 
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 assessments were not performed because all data gathered were de-identifiable; however, all 
local investigators were instructed on how to enrol patients and how to use the data collection 
platform as described in the study protocol, data dictionary and the instructional video. Sixth, 
cystic fibrosis (CF) is a frequent cause of chronic P. aeruginosa colonization, although the 
majority of patients with CF might be included in the bronchiectasis group, CF was not directly 
recorded in our study. Finally, the empiric selection of antibiotics and diagnostic approach was 
performed according to the health care provider and it was not according to pre-specified criteria. 
In conclusion, this multinational, point prevalence study found that the burden of P. 
aeruginosa, antibiotic-resistant P. aeruginosa, and multidrug-resistant P. aeruginosa as the 
etiologic pathogen of CAP is low (less than 5%). We identified five risk factors associated with 
P. aeruginosa-CAP: prior pseudomonas infection/colonization, tracheostomy, bronchiectasis, 
IRVS, and very severe COPD. These risk factors could serve to guide empiric anti-pseudomonal 
antibiotic treatment. Absence of these specific risk factors suggests that the empiric antibiotic 
treatment recommended for CAP patients will cover the most likely prevalent bacterial 
pathogens. Empiric anti-pseudomonal coverage should be reserved for a small subgroup of well- 
defined patients with a past medical history of pseudomonas infection/colonization and severe 
lung diseases (i.e., prior tracheostomy, bronchiectasis and/or very severe COPD), regardless of 
disease severity. Importantly, not all patients with chronic pulmonary diseases would require 
empiric antipseudomonal coverage for CAP.  
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Table 1. Characteristics of patients with Pseudomonas aeruginosa community-acquired pneumonia (CAP) vs 
non-P. aeruginosa-CAP.  
 
 
 
 
Variables 
 
CAP 
 
n=3,193 
n (%) 
 
P. aeruginosa CAP 
 
n= 133 
n (%) 
No- 
P. aeruginosa CAP 
 
n= 3,060 
n (%) 
 
 
p 
value 
 
 
Demographic characteristics, n (%) 
Age, median (IQR) years 68 (54, 80) 64.36 (52.5,78.5) 65.01 (54, 80) 0.748 
Male 1,877 (58.8) 79 (59.4) 1,798 (58.8) 0.883 
Underweight 150/2,055 
(7.3) 
9/89 (10.1) 141/1,966 (7.2) 0.297 
Obesity 510 (16) 17 (12.8) 493 (16.1) 0.305 
 
Respiratory past medical history, n (%) 
Active lung cancer 92 (2.9) 5 (3.8) 87 (2.8) 0.536 
Asthma 234 (7.3) 8 (6) 226 (7.4) 0.553 
Bronchiectasis 168 (5.3) 31 (23.3) 137 (4.5) <0.001 
Chronic aspiration 218 (6.8) 15 (11.3) 203 (6.6) 0.038 
COPD 834 (26.1) 57 (42.9) 777 (25.4) <0.001 
     Very severe COPD (FEV1 ≤30%) 90 (2.8) 16 (12.0) 74 (2.4) <0.001 
Current/former smoker 1,114 (34.9) 46 (34.6) 1,068 (34.9) 0.940 
Interstitial lung disease 91 (2.8) 6 (4.5) 85 (2.8) 0.240 
Obstructive sleep apnoea 123 (3.9) 6 (4.5) 117 (3.8) 0.687 
Oxygen therapy at home 208 (6.5) 26 (19.5) 182 (5.9) <0.001 
Lung transplantation 7 (0.2) 1 (0.8) 6 (0.2) 0.180 
Tracheostomy 50 (1.6) 15 (11.3) 35 (1.1) <0.001 
 
Cardiovascular past medical history, n (%) 
Arrhythmia 455 (14.2) 20 (15) 435 (14.2) 0.791 
Coronary artery disease 526 (16.5) 33 (24.8) 493 (16.1) 0.008 
Heart failure 418 (13.1) 25 (18.8) 393 (12.8) 0.046 
Hypertension 1,444 (45.2) 62 (46.6) 1,382 (45.2) 0.742 
Stroke 250 (7.8) 13 (5.2) 237 (7.7) 0.394 
 
Chronic medications, n (%) 
Inhaled corticosteroids use 544 (17) 48 (36.1) 496 (16.2) <0.001 
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 Proton pump inhibitor use 907 (28.4) 58 (6.4) 849 (27.7) <0.001 
Statins use 670 (21) 37 (27.8) 633 (20.7) 0.048 
Steroids use 268 (8.4) 21 (15.8) 268 (8.4) 0.002 
 
Chronic interventions, n (%) 
Enteric tube feeding 48 (1.5) 8 (6) 40 (1.3) <0.001 
Haemodialysis 51 (1.6) 4 (3) 47 (1.5) 0.185 
Indwelling catheter 67 (2.1) 11 (8.3) 56 (1.8) <0.001 
 
Immunosuppressive conditions, n (%) 
Active solid tumour 245 (7.7) 11 (4.5) 234 (7.6) 0.791 
AIDS 57 (1.8) 1 (0.8) 56 (1.8) 0.358 
Aplastic anaemia 13 (0.4) 0 (0) 13 (0.4) 0.451 
Asplenia 12 (0.4) 0 (0) 12 (0.4) 0.469 
Biological drug use 35 (1.1) 3 (2.3) 32 (1) 0.190 
Chemotherapy in the last 3 months 134 (4.2) 4 (3) 130 (4.2) 0.485 
Haematological malignancy 150 (4.70) 3 (2.3) 147 (4.8) 0.174 
HIV infection 107 (3.4) 3 (2.3) 104 (3.4) 0.473 
Immunocompromised patients 623 (19.5) 28 (21.1) 595 (19.4) 0.647 
Neutropenia 44 (1.4) 1 (0.8) 43 (1.4) 0.527 
Other immunosuppressive condition 125 (3.9) 11 (8.3) 114 (3.7) 0.008 
 
Other chronic medical conditions, n (%) 
Chronic renal failure 349 (10.9) 15 (11.3) 334 (10.9) 0.895 
Dementia 333 (10.4) 14 (10.5) 319 (10.4) 0.970 
Diabetes mellitus 681 (21.3) 28 (4.1) 653 (21.3) 0.937 
Liver disease 129 (4) 4 (3) 125 (4.1) 0.537 
Malnutrition 289 (9.1) 20 (15) 269 (8.8) 0.014 
Mental illness 220 (0.726) 10 (7.5) 210 (6.9) 0.770 
Prosthetic material 100 (3.1) 2 (1.5) 98 (3.2) 0.271 
Recurrent skin infections 55 (1.7) 4 (3.0)  51 (1.7) 0.245 
 
Other non-medical conditions, n (%) 
Bedridden 353 (11.1) 28 (21.1) 325 (92.1) <0.001 
Contact sport 5 (0.2) 0 (0) 5 (0.2) 0.641 
Healthcare worker 44 (1.4) 4 (3) 40 (1.3) 0.100 
Homeless 31 (1) 0 (0) 31 (1) 0.243 
Injection of illicit drugs 37 (1.2) 1 (0.8) 36 (1.2) 0.654 
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 Living in crowded conditions 671 (21) 24 (18) 647 (21.1) 0.391 
Nursing home resident 258 (8.1) 18 (13.5) 240 (7.8) 0.018 
Worker in livestock meat industry 29 (0.9) 0 (0) 29 (0.9) 0.259 
 
Previous infections/colonization, n (%) 
Prior MRSA infection/colonization 81 (2.5) 10 (7.5) 71 (2.3) <0.001 
Prior ESBL-producing bacterial infection 54 (1.7) 5 (3.8) 49 (1.6) 0.059 
Prior Pseudomonas aeruginosa infection/colonization 96 (3) 44 (33.1) 52 (1.7) <0.001 
 
Prior healthcare exposure, n (%) 
Antibiotic infusion at home during the last 12 months 140 (4.4) 12 (9) 128 (4.2) 0.008 
Emergency room admission in the last 12 months 972 (30.4) 63 (47.4) 909 (29.7) <0.001 
Hospitalizations during the last 12 months 1026 (32.1) 70 (52.6) 956 (31.2) <0.001 
IV antibiotics during the last 12 months 812 (25.4) 64 (48.1) 748 (24.4) <0.001 
LRTI in the last 12months 928 (29.1) 66 (49.6) 862 (28.5) <0.001 
Oral antibiotics during the last 12 months 1219 (38.2) 77 (57.9) 1142 (37.3) <0.001 
 
Pneumonia severity, n (%) 
Invasive respiratory or vasopressor support (IRVS) 404 (12.7) 34 (25.6) 370 (12.1) <0.001 
ICU admission 599 (18.8) 43 (32.3) 556 (18.2) <0.001 
Non-invasive mechanical ventilation 334 (10.5) 15 (11.3) 319 (10.4) 0.753 
CAP; Community-acquired pneumonia, MRSA; Methicillin resistant Staphylococcus aureus, COPD; Chronic obstructive pulmonary 
disease, FEV1; Forced expiratory volume during the first second, CAD; Coronary artery disease, ESBL; extended-spectrum beta-
lactamases, LRTI; lower respiratory tract infections 
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Table 2. Prevalence of antibiotic-resistant Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) 
and antibiotic-resistant P. aeruginosa-CAP in participating centres representing different continents. 
  
  
CAP patients  
n=3,193  
Continent  
  
Rest of the world 
  
OR (95% CI)  p 
value  
%  n  %  n  
  
Pseudomonas aeruginosa-CAP 
Global 4.2 133/3193 . . . . 
       Africa 5.5 7/128 4.1 126/3065 1.34 (0.61, 2.95) 0.57 
       Asia 5.2 21/405 4.0 112/2788 1.30 (0.81, 2.10) 0.27 
       Europe 3.8 73/1941 4.8 60/1252 0.77 (0.54, 1.10) 0.15 
       North America 4.3 21/484 4.1 112/2,709 1.0 (0.65, 1.69) 0.83 
       Oceania 3.1 1/32 4.2 132/3161 0.74 (0.10, 5.46) 0.76 
       South America 4.9 10/203 4.1 123/2990 1.20 (0.62, 2.33) 0.57 
 
Antibiotic resistant Pseudomonas aeruginosa-CAP 
Global   2  64/3193  .  .  .  .  
       Africa  3.9  5/128  1.9  59/3065  2.071 (0.817, 5.252)  0.125  
       Asia  2.2  9/405  2  55/2788  1.129 (0.554, 2.303)  0.738  
       Europe  1.6  32/1941  2.6  32/1252  0.639 (0.389, 1.049)  0.076  
       North America  2.5  12/484  1.9  52/2709  0.770 (0.408, 1.453)  0.420  
       Oceania  0  0/32  2  64/3161  .  0.416  
       South America  3  6/203  1.9  58/2990  1.540 (0.656, 3.612)  0.321  
 
Multi-drug resistant Pseudomonas aeruginosa-CAP (>3 antibiotics groups) 
Global   1.0  33/3193  .  .  .  .  
       Africa  2.3  3/128  1  30/3065  2.428 (0.731, 8.063)  0.135  
       Asia  0.5  2/405  1.1  31/2788  0.441 (0.105, 1.851)  0.250  
       Europe  0.9  18/1941  1.2  15/1252  0.772 (0.388, 1.537)  0.460  
       North America  1.2  6/484  1  27/2709  1.247 (0.512, 3.036)   0.626  
       Oceania  0  0/32  1  33/3161  .  0.561  
       South America  2  4/203  1  29/2990  2.052 (0.714, 5.895)  0.173  
 
Carbapenem resistant Pseudomonas aeruginosa-CAP 
Global   1.1  34/3193  .  .  .  .  
       Africa  1.6  2/128  1.0  32/3065  1.504 (0.357, 6.348) 0.576  
       Asia  0.7  3/405  1.1  31/2788  0.664 (0.202, 2.181) 0.496  
       Europe  0.9  18/1941  1.3  16/1252  0.723 (0.367, 1.423) 0.346  
       North America  1.7  8/484  1.0  26/2709  1.734 (0.781, 3.854) 0.171  
       Oceania  0  0/32  1.1  34/3161  . 0.555  
       South America  1.5  3/203  1.0  31/2990  1.432 (0.434, 4.724) 0.554  
 
Colistin resistant Pseudomonas aeruginosa-CAP 
Global   0.4  12/3193  .  .  .  .  
       Africa  0  0/128  0.4  12/3065  .  0.478  
       Asia  0.7  3/405  0.3  9/2788  2.304 (0.621, 8.547)  0.199  
       Europe  0.4  7/1941  0.4  5/1252  0.903 (0.286, 2.850)  0.861  
       North America  0  0/484  0.4  12/2709  .  0.142  
       Oceania  3.1  1/32  0.3  11/3161  9.238 (1.157, 73.754)  0.011  
       South America  0.5  1/203  0.4  11/2990  1.341 (0.172, 10.436)  0.779  
38
 Table 3. Multivariate analysis of risk factors for Pseudomonas aeruginosa-Community-acquired pneumonia (CAP), antibiotic resistant (AR) P. 
aeruginosa-CAP, multidrug-resistant (MDR) P. aeruginosa-CAP, and specific antibiotic resistance patterns. 
 Prior P. aeruginosa IRVS Tracheostomy Bronchiectasis COPD Very severe COPD 
 
P. aeruginosa-CAP, n=133 
 
16.10 (9.48-27.35) 
 
2.33 (1.44-3.78) 
 
6.50 (2.61-16.19) 
 
2.88 (1.65-5.05) 
 
. 
 
2.76 (1.25-6.06) 
 
AR P. aeruginosa-CAP, n=64 
 
17.29 (9.95-33.42) 
 
3.12 (1.63-5.97) 
 
5.55 (1.73-17.80) 
 
. 
 
. 
 
. 
    
   Anti-pseudomonal cephalosporins, n=38 
 
17.79 (7.32-43.22) 
 
. 
 
. 
 
. 
 
2.58 (1.07-6.19) 
 
. 
   Piperacillin/ Tazobactam, n=30 9.72 (3.88-24.36) 4.14 (1.75-9.81) . 3.33 (1.21-9.19) . . 
   Carbapenems, n=34 10.62 (4.26-26.45) 2.70 (1.14-6.34) 10.77 (3.09-37.52) . . . 
   Aminoglycosides, n=31 17.32 (7.21-41.61) 3.02 (1.24-7.31) . . . . 
   Quinolones, n=50 17.35 (8.28-36.38) 2.84 (1.39-5.78) 4.35 (1.21-15.60) . . . 
 
MDR P. aeruginosa- CAP, n=33 
 
12.34 (5.05-30.14) 
 
3.42 (1.47-7.97) 
 
. 
 
. 
 
2.69 (1.10-6.55) 
 
. 
IRVS, invasive respiratory or vasopressor support; MDR, multidrug resistant, COPD, chronic obstructive pulmonary disease. 
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 FIGURE LEGENDS  
Figure 1. Prevalence of Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) and 
antibiotic-resistant P. aeruginosa-CAP by continents (Panel A and Panel B).  
 
Figure 2. Prevalence of Pseudomonas aeruginosa-Community-acquired pneumonia (CAP) 
according to the relevant risk factors that include prior Pseudomonas aeruginosa (pPa) 
infection/colonization, grouped variables of severe lung diseases (LDz3: tracheostomy, 
bronchiectasis and very severe COPD [i.e., FEV1 <30%]) and stratified according to the need of 
invasive respiratory and/or vasopressor support (IRVS). 
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